By Fineline Cube Hangzhou-based artificial intelligence (AI)-driven biotech MindRank AI has announced obtaining approval from the US FDA to conduct a clinical study for its oral, small molecule GLP-1 receptor agonist (RA) drug MDR-001 in obesity. This marks a significant milestone in the development of MDR-001, positioning MindRank AI to advance its innovative therapeutic candidate.
Drug Profile and Development
MDR-001, discovered by Molecule Pro, an AI pharmaceutical platform developed by MindRank AI, is a new oral small molecule GLP-1 receptor agonist. It can be used to treat obesity, type 2 diabetes, and other indications. In preclinical studies, MDR-001 demonstrated excellent efficacy and selectivity, good ADME (absorption, distribution, metabolism, and excretion) and oral bioavailability, and outstanding pharmacokinetic characteristics, indicating best-in-class potential.
Future Prospects and Strategic Implications
A Phase I study for MDR-001 is expected to commence during the first quarter of 2023. This clinical trial will provide valuable insights into the safety and efficacy of MDR-001 in treating obesity, potentially paving the way for its future approval and commercialization. The FDA’s approval underscores MindRank AI’s commitment to leveraging AI technology to develop innovative therapies that address significant unmet medical needs.-Fineline Info & Tech